Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir versus lopinavir-ritonavir in hospitalized adults with COVID-19 pneumonia
IRCT20151227025726N14Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of favipiravir, lopinavir and ritonavir in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Fever, Cough and 3 more. Started Apr 2020; status: completed.
02
Drugs
favipiravirlopinavirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20151227025726N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151227025726N14.